Skip to main content

TGA provisionally approves the Biocelect Pty Ltd (Novavax) COVID-19 vaccine, NUVAXOVID, for use in individuals aged 12-17 years

The TGA has granted provisional approval to Biocelect Pty Ltd (on behalf of Novavax Inc) for its COVID-19 vaccine, NUVAXOVID.

Last updated

Help us improve the Therapeutic Goods Administration site